Skip to main content

Table 1 Characteristics of the participants at baseline

From: Adherence to inhaled therapy and its impact on chronic obstructive pulmonary disease (COPD)

 

All

Female

Male

p-value

n (%)

357

122 (34.2)

235 (65.8)

 

Age in year, mean (SD)

66.5 (10.6)

66.1 (11.1)

66.7 (10.0)

0.580

FEV1%pred., mean (SD)

55.0 (18.5)

58.0 (19.4)

53.4 (17.9)

0.067

Smoking status, n (%)

 Current smoker

126 (35.3)

43 (35.3)

83 (35.3)

0.982

 Former smoker

205 (57.4)

67 (54.9)

138 (58.7)

0.471

 Never smoker

14 (3.9)

8 (6.5)

6 (2.6)

0.065

 No information

12 (3.4)

4 (3.3)

8 (3.4)

 

Inhaled Therapy, n (%)

 LAMA only

10 (2.8)

3 (2.5)

7 (3.0)

0.777

 LABA only

3 (0.8)

2 (1.6)

1 (0.4)

0.233

 LABA + ICS

64 (17.9)

34 (27.9)

30 (12.8)

<  0.001

 LAMA + LABA + ICS

275 (77.0)

80 (65.6)

195 (83.0)

<  0.001

 LABA + LAMA

5 (1.4)

3 (2.5)

2 (0.9)

0.952

LTOT, n (%)

60 (17.0)

26 (21.5)

34 (14.7)

0.101

  1. LAMA – long-acting muscarinic antagonist; LABA – long-acting beta-adrenoceptor agonist; ICS – inhaled corticosteroid; LTOT – long-term oxygen therapy